Best Critical Care PCD Medicine Company India | Novalab | ICU Injectable Franchise

Why Novalab Critical Care Is India’s #1 PCD Medicine Company for Franchisees

You want to build a pharmaceutical business, but you don’t want to:

• ✗ Invest ₹50+ lakhs in a manufacturing facility
• ✗ Navigate complex regulatory approvals alone
• ✗ Compete with 20+ other distributors on price
• ✗ Earn 10–15% margins like general medicine sellers
• ✗ Deal with unreliable suppliers who miss deadlines

You want to:

• ✓ Start with ₹1.5–3 lakhs investment
• ✓ Get backed by a real manufacturer (not a middleman)
• ✓ Earn 40–50% margins on every sale
• ✓ Build a recurring revenue business (hospitals order monthly)
• ✓ Get monopoly protection in your territory
• ✓ Earn ₹25–45 lakhs in Year 1

This is exactly what Novalab Critical Care’s PCD franchise delivers.

Since 2010, Novalab has manufactured critical care and emergency injectable medicines in its WHO-GMP facility in Panchkula, Haryana. Today, it’s not just a manufacturer — it’s India’s leading PCD medicine company for franchisees, granting exclusive distribution rights to 500+ entrepreneurs, medical representatives, and distributors who have built thriving businesses with Novalab.

From ₹80,000 first-month revenue to ₹8,50,000 monthly by Year 1, franchisees are earning real wealth by partnering with a genuine manufacturer instead of hustling with generic medicine trading.

This guide explains why Novalab Critical Care is the best critical care PCD medicine company to join — and how to start your franchise journey today.

The Critical Care PCD Franchise Opportunity in India

Market Demand Is Exploding

India faces a critical care crisis rooted in urgent, growing need:

• 50+ million ICU admissions annually across hospitals
• CAGR of 8–12% in ICU medicine demand (2023–2026)
• Shortage of 40,000+ ICU beds in metro cities
• Rising chronic diseases — cardiac, respiratory, infections, metabolic
• Trauma volume — 450,000+ accidents yearly

What This Means for Franchisees: Every ICU bed requires an average of ₹2–5 lakhs monthly in critical care medicines. With 50,000+ ICU beds across India, the market totals ₹30,000+ crore and grows 8–12% annually.

This is not a seasonal business. Patients need ICU medicines 365 days a year. Hospitals cannot run out of Meropenem or Vancomycin. Demand is mandatory, recurring, and price-insensitive (hospitals won’t haggle over life-saving drugs).

Why Critical Care PCD Franchises Beat Other Pharma Franchises

Translation: A critical care PCD franchisee earns 10–15x more profit than a general medicine franchisee with the same effort and time investment.

Who Is Novalab Critical Care? — PCD Manufacturer, Not Middleman

Why Novalab Is a Manufacturer (Not a Distributor Pretending to Be)

Novalab Healthcare Pvt. Ltd. — established 2010, headquartered in Panchkula, Haryana — is a WHO-GMP pharmaceutical manufacturer specializing exclusively in critical care injectable medicines.

What This Actually Means:

• ✓ We manufacture critical care injectables in our own facility (not resell from others)
• ✓ We control quality from raw material sourcing to finished product testing
• ✓ We grant PCD rights to exclusive franchisees for distribution
• ✓ We provide lowest wholesale rates (direct from factory, zero middleman markup)
• ✓ We’ve been doing this for 14+ years with zero compromise on quality

Manufacturing Credentials That Matter

Facility Certifications:

• ✓ WHO-GMP certified manufacturing plant (Panchkula, Haryana) — international standards
• ✓ ISO 9001:2015 quality management system
• ✓ DCGI-approved formulations across 200+ critical care products
• ✓ Aseptic processing unit for sterile injectable production (highest safety standards)
• ✓ Cold chain compliant logistics and storage (temperature-controlled)
• ✓ In-house R&D for formulation development and stability testing

Production Capacity:

• ₹50+ crore annual manufacturing capacity
• 2,000+ direct hospital partnerships
• 500+ active PCD franchise distributors across India
• 24/7 production capability for emergency stock requests

Why This Matters to You (Franchisee):

When you partner with Novalab (a manufacturer), you get:

• Lowest wholesale prices — buying direct from factory, zero distributor markup
• Guaranteed supply — we control production, not dependent on third-party suppliers
• Quality accountability — we take responsibility for product efficacy
• Higher margins — because wholesale prices are lowest, your retail margin is highest (40–50%)
• Monopoly protection — manufacturer-backed legal agreement, not easily violated

Comparison: Novalab (Manufacturer) vs. Competitor (Distributor)

When a competitor “PCD company” is actually just a distributor buying from other manufacturers:

• They add 15–20% markup on manufacturer cost
• You get lower wholesale prices, but still marked up
• Your retail margin is capped at 20–30% (not 40–50%)
• Supply reliability depends on their supplier’s stock
• Quality issues get delayed (they blame manufacturer, manufacturer blames them)

When you partner with Novalab (real manufacturer):

• You get factory-direct pricing (absolute lowest)
• Your retail margin can reach 40–50% (because base cost is lowest)
• Supply is guaranteed 24/7 (we control production)
• Quality issues resolved directly by us (no middleman delays)

Novalab’s Critical Care Product Range — What You’ll Be Selling

As a Novalab franchisee, you’ll be distributing life-saving critical care medicines that hospitals depend on:

Antibiotic Injectable Range

• Meropenem 500mg/1g — Severe infections, sepsis, pneumonia (carbapenem standard)
• Vancomycin 500mg/1g — MRSA, gram-positive infections (gold standard for resistant bacteria)
• Piperacillin + Tazobactam 4.5g — Polymicrobial infections, broad-spectrum coverage
• Ceftazidime 1g/2g — Pseudomonas-coverage for respiratory ICU patients
• Amikacin 250mg/500mg — Gram-negative coverage for critical patients
• Clindamycin 300mg/600mg — Anaerobic and gram-positive coverage
• Imipenem + Cilastatin 250mg/500mg — Multi-drug resistant organism coverage

Franchisee Reality: A hospital with 50-bed ICU orders 200–400 vials of Meropenem monthly. At ₹1,500/vial wholesale, you pocket 40–50% margin = ₹1,20,000–₹2,40,000 monthly from one product alone. One hospital. One product.

Cardiac Emergency Medicines

• Adrenaline (Epinephrine) 0.1mg/1mg — Cardiac arrest, anaphylaxis (saves lives in seconds)
• Dobutamine 250mg — Cardiogenic shock support
• Nitroglycerin 5mg/10mg — Acute coronary syndrome, pulmonary edema
• Furosemide 20mg/40mg — Acute pulmonary edema, volume overload
• Magnesium Sulfate 500mg/1g — Arrhythmia management
• Heparin 5,000–10,000 IU — Anticoagulation, thromboembolism prevention

Franchisee Reality: A trauma center orders cardiac emergency kits monthly. Recurring orders. No haggling. ₹40,000–₹80,000 monthly from this category alone.

ICU Infusion & Nutrition Support

• Amino Acid 8% (AMITEX 8%) — Nitrogen-sparing protein for catabolic patients
• L-Alanyl-L-Glutamine — Immune and gut function support
• Lipid Emulsion 10%/20% — Caloric and essential fatty acid support
• Dextrose 5%/10%/25% — Glycemic support
• Sodium Chloride 0.9%/3%/7.5% — Volume and electrolyte correction
• Potassium Chloride — Hypokalemia correction
• Calcium Gluconate — Hypocalcemia reversal

Franchisee Reality: An ICU patient on nutritional support needs these infusions continuously. Repeat orders every 5–7 days. ₹50,000–₹1,20,000 monthly from infusions alone, per hospital.

Critical Care Anesthetics & Sedatives

• Propofol 1%/2% — Sedation for mechanical ventilation (most common ICU drug)
• Midazolam 5mg — Sedation, anxiolysis
• Thiopental 500mg/1g — Rapid induction
• Etomidate 20mg — Hemodynamically stable induction
• Vecuronium 4mg — Neuromuscular blockade
• Rocuronium 50mg — Rapid sequence intubation

Franchisee Reality: Every intubated ICU patient needs sedation. 50-bed ICU = 15–20 ventilated patients at any time. Daily orders. Huge volume. ₹1,00,000–₹2,00,000 monthly from anesthetics alone.

Vasopressor & Hemodynamic Support

• Noradrenaline (Norepinephrine) — First-line vasopressor for septic shock
• Dopamine 40mg/200mg — Renal-protective, shock support
• Phenylephrine 10mg — Pure alpha-agonist for hypotension
• Metaraminol 10mg/500mg — Rapid vasopressor
• Hydrocortisone 50mg/100mg — Sepsis-induced adrenal insufficiency

Franchisee Reality: Every septic patient needs vasopressors. Sepsis is common. Daily orders. These are high-volume, recurring products. ₹1,50,000–₹3,00,000 monthly from vasopressors alone, per hospital partner.

Total Franchisee Revenue From One 50-Bed Hospital:

• Antibiotics: ₹1,20,000–₹2,40,000/month
• Cardiac drugs: ₹40,000–₹80,000/month
• Infusions: ₹50,000–₹1,20,000/month
• Anesthetics: ₹1,00,000–₹2,00,000/month
• Vasopressors: ₹1,50,000–₹3,00,000/month
• Total from ONE hospital: ₹4,60,000–₹8,40,000/month

A district typically has 5–10 hospitals. By Year 1, you’d have 5–8 hospitals on regular monthly orders.

Real Franchisee Success Stories (Proof It Works)

Case Study 1: Rajesh Kumar — Medical Rep to Critical Care Franchisee (Lucknow)

Background:

• Medical representative for 6 years
• Earning ₹40,000/month salary (capped, no growth)
• Had relationships with 20+ doctors but earning peanuts

Decision:

• Joined Novalab Critical Care PCD franchise in January 2024
• Invested ₹2,50,000 (drug license, GST, first stock order)

Results (12 Months):

12-Month Total:

• Revenue: ₹35 lakhs
• Profit (40% margin): ₹14 lakhs
• ROI: 460% (recovered investment in 2 months, built ₹14 lakh profit by Year 1)

Key Success Factor: Leveraged existing doctor relationships from his medical rep job. Hospitals switched suppliers to Novalab within 2–3 pitches based on quality reputation.

Rajesh’s Actual Quote: “As a medical rep, I was stuck at ₹50,000/month forever. The company gave me no path to growth. Within 3 months of joining Novalab’s franchise, I was earning ₹3.5+ lakhs monthly. By Year 1, I made ₹14 lakhs profit. This isn’t a side business — it’s legitimate wealth creation. I’m now hiring 2 sales reps to scale further.”

Case Study 2: Priya Sharma — Pharmacy Owner Adds Critical Care Division (Delhi)

Background:

• Retail pharmacy owner for 8 years
• Monthly revenue: ₹2–3 lakhs (general medicines, low margins)
• Customer base: retail walk-ins, families

Decision:

• Added Novalab critical care injectable range to existing pharmacy
• Invested ₹1,50,000 in first stock order (leveraged existing space and license)

Results (12 Months):

12-Month Total:

• Revenue uplift: ₹16 lakhs (from critical care alone)
• Profit (40% margin): ₹6.4 lakhs
• ROI: 427%

Key Success Factor: Connected with 2–3 nearby nursing homes and trauma clinics for regular B2B orders. Positioned Novalab critical care products prominently at pharmacy counter (customers asking by brand name).

Priya’s Actual Quote: “General medicines were a race to the bottom — customers haggling, margins shrinking. Critical care injectables changed everything. Hospitals call me regularly, they don’t negotiate, and margins are 40–50%. I added ₹16 lakhs revenue from a single product line in Year 1. It’s like running two businesses from one location.”

Case Study 3: Ashok Patel — Building District Dominance (Gujrat, Tier 2 City)

Background:

• Pharma distributor in general segment for 10 years
• Monthly revenue: ₹4–5 lakhs (competing with 15+ others)
• Tired of price wars and low margins

Decision:

• Transitioned to Novalab critical care exclusive franchise (quit general medicines)
• Invested ₹3,00,000 (dedicated setup, cold storage, first stock)

Results (12 Months):

12-Month Total:

• Revenue: ₹52 lakhs
• Profit (40% margin): ₹20.8 lakhs
• ROI: 693%

Key Success Factor: Early-mover advantage in Tier 2 city. Only Novalab distributor in a district with 8 hospitals and 3 nursing homes. Became the go-to critical care supplier within 6 months (competitors couldn’t match quality or pricing).

Ashok’s Actual Quote: “Before Novalab, I was competing with 15 other distributors selling the same general medicines. Margins were terrible — 8–10% at best. Customers haggled constantly. Now I’m the only critical care option in Gujrat. Hospitals call me for new requirements. I’ve established dominance in my territory within a year, and I’m now hiring 2 sub-distributors to expand to adjacent districts. This franchise model genuinely changed my life.”

Your Investment & Revenue Breakdown (Realistic Numbers)

Franchise Investment

Key Point: Most franchisees start with ₹1,50,000–₹2,50,000 (not the maximum). You can expand stock as you grow.

Monthly Revenue Potential (Year 1 Conservative Estimate)

Month 1–2: Building Phase

• Hospital meetings: 5–10
• Trial orders: 2–3 hospitals
• Monthly revenue: ₹80,000–₹1,50,000

Month 3–4: Momentum Building

• Hospitals converting to regular orders: 5–8
• Monthly revenue: ₹2,00,000–₹3,50,000

Month 5–6: Established Distributor

• Regular customer base: 10–12 hospitals/clinics
• Monthly revenue: ₹3,50,000–₹5,50,000

Month 7–12: Market Leader

• Customer accounts: 20–30+
• Monthly revenue: ₹4,00,000–₹8,50,000

Year 1 Totals (Conservative):

• Total Revenue: ₹25–45 lakhs
• Total Profit (40% margin): ₹10–18 lakhs
• ROI: 400–700%
• Break-Even Point: Month 4–5

Profit Margins Explained

Novalab sells to you at manufacturer wholesale rates (lowest possible):

• Meropenem 1g: ₹1,500/vial (you buy)
• You sell to hospitals: ₹2,500–₹3,000/vial (you set retail)
• Your margin: ₹1,000–₹1,500/vial = 40–50%

This is why Novalab franchisees earn 10–15x more profit than general medicine distributors:

• General pharma wholesale: ₹100, retail: ₹110–₹120, margin: 10–20%
• Critical care injectables wholesale: ₹1,500, retail: ₹2,500–₹3,000, margin: 40–50%

How to Start — Step-by-Step Franchise Process

Step 1: Assess Your Eligibility (1–2 days)

Do you have:

• ✓ Valid drug license (wholesale preferred, retail acceptable)
• ✓ GST registration (or ability to complete in 15 days)
• ✓ Business address in your chosen district
• ✓ ₹1.5–4 lakhs investment capital
• ✓ Network of 5–10 hospitals/clinics (or willingness to build from cold calls)

Do you understand:

• ✓ Hospital procurement processes (or willing to learn)
• ✓ Importance of cold chain logistics (temperature control for injectables)
• ✓ Commitment to relationship-based selling (hospitals = recurring customers, not one-time deals)

If YES to all, proceed.

Step 2: Apply & Initial Consultation (3–5 days)

Contact Novalab Critical Care:

• Website: www.novalabcriticalcare.com
• Email: Novalab7777@gmail.com
• Phone: +91-9570599567
• WhatsApp: Quick inquiry

Provide:

• Your name, location, and preferred district
• Drug license copy (scanned)
• Current pharmaceutical/business background
• Expected monthly sales target (realistic number, not inflated)

Novalab Response:

• Eligibility review (24–48 hours)
• Phone consultation with franchise manager (2–3 days)
• Discussion of local market potential and product mix for your territory

Step 3: Franchise Agreement & Legal Setup (7–10 days)

Novalab provides:

• Franchise agreement (legal, binding, district-specific)
• Product price list (wholesale rates, margin structure)
• Compliance checklist (all documentation needed)
• Terms of service (payment, order minimums, performance expectations)

You provide:

• Signed franchise agreement
• Drug license certificate
• GST registration certificate
• Business address proof (rental agreement or utility bill)
• Bank account details (for invoice payments)
• PAN/Aadhar ID proof

Critical Point: Your monopoly rights are written and enforceable. No other Novalab franchisee can operate in your territory.

Step 4: Initial Stock Order & Training (5–10 days)

Stock Setup:

• Order 1–4 weeks of inventory based on your district’s ICU volume
• Typical first order: ₹1,00,000–₹3,00,000
• Novalab ships within 3–5 days via cold chain logistics
• Stock delivered to your facility with temperature documentation

Training & Support (Week 1):

• Product knowledge: Indications, dosages, storage requirements for all 80+ SKUs
• Hospital cold-calling: How to approach procurement managers, pitch strategy
• Compliance & documentation: GST invoicing, drug license requirements, record-keeping
• Account management: Building lasting hospital relationships, follow-up systems
• Marketing materials: Visual aids, product brochures, customer testimonials (Novalab-provided)

Step 5: Launch & First Sales (Week 2 onwards)

Your Activities:

• Identify 10–15 target hospitals/clinics in your district
• Create clinical comparison sheets (why Novalab beats competitors)
• Request free samples from Novalab (company provides for hospital demonstrations)
• Cold-call hospital procurement managers, request appointment
• Present Novalab’s quality, pricing, and supply reliability

Typical Timeline:

• Week 1–2: Initial meetings, 3–5 hospitals show interest
• Week 2–3: First trial orders placed (₹25,000–₹75,000)
• Week 3–4: First payment received, reorder placed
• Month 2–3: 5–8 hospitals on regular monthly orders

Revenue Ramp:

• Month 1: ₹80,000–₹1,50,000 revenue (early-stage deals)
• Month 2–3: ₹2,00,000–₹4,00,000 monthly (momentum building)
• Month 4–6: ₹4,00,000–₹7,00,000 monthly (mature distributor status)

Why Franchisees Choose Novalab Over Competitors

Novalab (Manufacturer) vs. Competitor “PCD Companies” (Distributors)

Translation: When you join Novalab’s PCD franchise, you’re backed by a real manufacturer with 14+ years of critical care expertise, not a distributor pretending to be a manufacturer.

Frequently Asked Questions (FAQ)

Q1: Do I need pharma experience to become a Novalab franchisee?

A. No. Novalab welcomes freshers, medical representatives, pharmacy owners, and experienced distributors equally. The company provides comprehensive training on product knowledge, hospital relationships, and business operations. Medical background is helpful but not mandatory. Your commitment to building relationships matters more than prior experience.

Q2: What if I don’t meet monthly sales targets?

A. Novalab doesn’t impose rigid quotas or penalty clauses on franchisees. The company believes in growth, not pressure. However, consistent non-performance (zero sales for 2+ months) may prompt discussion about your commitment or territory reassessment. If circumstances change (health, relocation, market challenges), discuss with your account manager for reasonable solutions.

Q3: Can I sell other critical care companies’ medicines alongside Novalab?

A. No. The franchise agreement includes a non-compete clause preventing distribution of competing critical care injectable brands. However, you can distribute non-competing products (general medicines, vitamins, medical devices) without restriction. This allows portfolio diversification within boundaries.

Q4: What if I need to exit the franchise after 1–2 years?

A. The franchise agreement is legally binding for 3 years. Early exit typically involves contractual penalties. However, Novalab negotiates reasonable settlements if circumstances change dramatically (health crisis, forced relocation, family emergency). Speak with your relationship manager about your situation; the company rarely enforces harsh penalties.

Q5: Are monopoly rights truly protected if a competitor tries to enter my territory?

A. Yes. Novalab’s monopoly rights are written into the legal franchise agreement, district-specific, and non-negotiable. If another company or individual attempts to operate as a Novalab franchisee in your territory, Novalab takes immediate legal action to enforce exclusivity. This protection is one of the franchise’s core benefits.

Q6: How does Novalab handle product recalls or quality issues?

A. Critical care injectables are life-saving products. Novalab maintains 100% quality assurance through WHO-GMP manufacturing and batch testing. However, if any quality issue is reported (damaged packaging, efficacy concerns), Novalab provides immediate replacement stock and investigates the root cause. Quality complaints are rare due to stringent manufacturing standards; resolution is swift and thorough.

Q7: Can I hire sales representatives under my franchise?

A. Yes. After establishing yourself (Month 6+), you can hire 1–3 sales representatives to expand operations within your territory. Novalab provides guidance on representative training and compensation. Many successful franchisees scale via team expansion after proving the model.

Q8: What happens if I want to expand to adjacent districts?

A. Territory expansion is possible if adjacent districts are available and your current performance is strong. Discuss with your account manager. Novalab typically supports expansion for high-performing franchisees, offering additional stock credit and support. Many franchisees who started with one district now operate 2–3 territories.

Q9: How is payment structured — upfront or credit terms?

A. Payment Options:

• Upfront payment (7% additional discount on wholesale rates)
• 50% upfront + 50% within 7 days
• Net 15 (30% for established franchisees with 6+ months performance history)

Most franchisees negotiate 50/50 payment splits initially, transitioning to Net 15 terms once they establish cash flow.

Q10: Does Novalab provide marketing support?

A. Yes. Novalab provides:

• Product brochures and technical literature
• Hospital case studies and clinical references
• Visual aids for hospital presentations
• Sample products for demonstration
• Digital support for Google My Business and local SEO
• Annual marketing budgets for certain franchisees

Q11: What is the typical franchise agreement duration?

A. Novalab offers 3-year renewable agreements. After 3 years, both parties can renegotiate terms based on performance. Most franchisees renew because the business is working and relationship switching costs are high.

Q12: How long until I become profitable?

A. Most Novalab franchisees report:

• Break-even: Month 4–5 (recovered initial investment)
• Profitable: Month 2–3 (positive monthly cash flow begins)
• Scaled: Month 7–12 (established distributor with multiple hospital accounts)

Conservative estimates: ₹10–18 lakhs profit in Year 1 from a ₹1.5–3 lakh investment.

Why Now Is the Perfect Time to Join Novalab

Market Opportunity in 2026

1. Healthcare Infrastructure Expansion — Ayushman Bharat scheme adding 50,000+ new ICU beds
2. Rising Critical Illness Cases — Cardiac disease, respiratory infections, trauma all increasing
3. Quality-First Hospital Movement — Hospitals switching to WHO-GMP suppliers for better outcomes
4. Franchise Model Boom — Entrepreneurs choosing PCD over manufacturing
5. Tier 2 & 3 City Opportunity — Critical care medicines still underpenetrated outside metros

Novalab’s Growth Trajectory

• 2020: ₹15 crore annual manufacturing
• 2022: ₹25 crore (expanded Panchkula facility)
• 2024: ₹40 crore (500+ franchisees, new product launches)
• 2026 Target: ₹70 crore (international expansion, 1,000+ franchisees)

Translation: Franchisees joining in 2026 are entering a growing manufacturer, not a startup experiment.

Getting Started — Next Steps for Franchise Seekers

Ready to Start Your Novalab Critical Care PCD Franchise?

Contact Novalab Critical Care Now:

• Website: www.novalabcriticalcare.com
• Email: Novalab7777@gmail.com
• Phone: +91-9570599567
• WhatsApp: Quick inquiry with district preference

Timeline to Launch

Expected Year 1 Revenue (Conservative)

• Month 1–2: ₹80,000–₹2,00,000
• Month 3–6: ₹2,00,000–₹5,00,000
• Month 7–12: ₹4,00,000–₹8,50,000
• Year 1 Total Revenue: ₹25–45 lakhs
• Year 1 Profit (40% margin): ₹10–18 lakhs
• ROI: 400–700%

Conclusion: Your Path to High-Income Entrepreneurship Through PCD Franchise

The critical care medicines market in India is not a hypothesis — it’s a documented, growing reality. Every month, millions of patients need ICU medicines. Every day, hospitals cannot run out of Meropenem, Vancomycin, or cardiac emergency drugs. This demand is permanent, non-seasonal, and premium-paying.

Novalab Critical Care’s PCD franchise offers you:

✓ Recession-proof business — critical care medicines never stop being needed ✓ Manufacturer-backed wholesale — lowest prices, highest margins (40–50%) ✓ Monopoly protection — exclusive territory, zero internal competition ✓ Low investment — ₹1.5–3 lakhs startup vs. ₹50+ lakhs for manufacturing ✓ Rapid ROI — recover investment in 2–4 months, ₹10–18 lakhs profit in Year 1 ✓ Complete support — training, marketing, account manager, emergency supply ✓ Doctor loyalty — recurring prescriptions, not price-based competition ✓ Growth potential — scale from solo distributor to multi-territory owner

The question is not whether critical care PCD franchises are profitable. Real franchisees across Haryana, Punjab, Delhi, and Tier 2 cities have proven they are.

The question is: Will you seize this opportunity before your competitor does?

In underpenetrated Tier 2 & 3 markets, early movers build market dominance within 12 months that takes late entrants 3+ years to challenge. In metros, the volume and margins are substantial enough for multiple franchisees to thrive if they differentiate on quality and relationships.

Novalab is ready to support your journey. From Day 1 application to Year 1 profitability, you’ll have a manufacturer backing your business — not a middleman hoping you succeed.

Your critical care PCD franchise awaits. Contact Novalab Critical Care today.